Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4

Cancer

Volumn 116, Issue SUPPL. 11, 2010, Pages 2806-2814

  Robertson, Fredika M ^a   Simeone, Ann Marie ^a   Lucci, Anthony ^a   McMurray, John S ^a   Ghosh, Sukhen ^a   Cristofanilli, Massimo ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Cyclooxygenase 2; Inflammatory breast cancer; Invasion; Matrix metalloprotease 2; Prostaglandin E2; Prostanoid receptor 3; Prostanoid receptor 4; Vasculogenic mimicry

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GW 627368X; MESSENGER RNA; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID RECEPTOR; PROSTANOID RECEPTOR EP3; PROSTANOID RECEPTOR EP4; SHORT HAIRPIN RNA; SULPROSTONE; UNCLASSIFIED DRUG; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; TUMOR PROTEIN;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATORY BREAST CANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; WESTERN BLOTTING; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CYCLOOXYGENASE 2 GENE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE SILENCING; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GENE; ZYMOGRAPHY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; ISOINDOLES; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDINS E; RECEPTORS, PROSTAGLANDIN E; SULFONAMIDES;

EID: 77952737323     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25167     Document Type: Conference Paper

References (31)

1. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer [review]. Semin Oncol. 2008;35:64-71. (Pubitemid 351282392)
2. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center Cancer. Chemother Pharmacol. 1997;40:321-329.
3. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832-5838.
4. Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphate cooperate in the development of inflammatory breast cancer [serial online]. Breast Cancer Res. 2004;6:R110-R115.
5. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965-7971.
6. Bays DE. Xanthone derivates. US Patent US3755319 (A). August 28, 1973.
7. Wilson RJ, Giblin GM, Roomans S, et al. GW627368X ((N-{2-[4-(4,9- diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006;148:326-339.
8. Maniotis AJ, Folberg R, Hess A,et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739-752.
9. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma [review]. Nat Rev Cancer. 2003;3:411-421.
10. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Intl J Oncol. 1997;10:503-507. (Pubitemid 27122013)
11. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429-434. (Pubitemid 34620779)
12. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003;9:2651-2656. (Pubitemid 36842109)
13. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978-2987.
14. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene. 2007;26:3789-3796. (Pubitemid 46878131)
15. Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA, Robertson FM. Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat. 2004;73:249-264.
16. Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27:719-727.
17. Basu GD, Liang WS, Stephan DA, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells [serial online]. Breast Cancer Res. 2006;8:R69.
18. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005;7:R422-R435.
19. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
20. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31(2 suppl 7):22-29. (Pubitemid 38879411)
21. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors [review]. JAMA. 2001;286:954-959. (Pubitemid 33010342)
22. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
23. Sugimoto Y, Narumiya S. Prostaglandin E receptors [review]. J Biol Chem. 2007;282:11613-11617.
24. Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. Sci World J. 2007;7:1329-1347.
25. Ushikubi F, Sugimoto Y, Ichikawa A, Narumiya S. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors [review]. Jpn J Pharmacol. 2000;83: 279-285.
26. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
27. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res. 2003; 289:265-274.
28. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis [review]. Cancer Res. 2006; 66:9794-9797. (Pubitemid 44672027)
29. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 2006;66:2923-2927.
30. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res. 2006;66:9665-9672.
31. Robertson FM, Simeone AM, Mazumdar A, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol. 2008;7:299-312.